Gatenby RA, Gillies RJ: A microenvironmental model of carcinogenesis. Nat Rev Cancer. 2008, 8: 56-61. 10.1038/nrc2255.
Article
CAS
PubMed
Google Scholar
Majmundar AJ, Wong WJ, Simon MC: Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010, 40: 294-309. 10.1016/j.molcel.2010.09.022.
Article
CAS
PubMed
PubMed Central
Google Scholar
Semenza GL: HIF-1 and human disease: one highly involved factor. Genes Dev. 2000, 14: 1983-1991.
CAS
PubMed
Google Scholar
Sporn MB, Liby KT: NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012, 12: 564-571. 10.1038/nrc3278.
Article
CAS
PubMed
Google Scholar
Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT: Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. Breast Cancer Res. 2011, 13: R62-10.1186/bcr2899.
Article
PubMed
PubMed Central
Google Scholar
Hetz C, Martinon F, Rodriguez D, Glimcher LH: The unfolded protein response: integrating stress signals through the stress sensor IRE1alpha. Physiol Rev. 2011, 91: 1219-1243. 10.1152/physrev.00001.2011.
Article
CAS
PubMed
Google Scholar
Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee AH, Yoshida H, Mori K, Glimcher LH, Denko NC, Giaccia AJ, Le QT, Koong AC: XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 2004, 64: 59435947-10.1158/0008-5472.CAN-04-1606.
Article
Google Scholar
Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen Y, Mai J, Shen H, Hu DZ, Adoro S, Hu B, Song M, Tan C, Landis MD, Ferrari M, Shin SJ, Brown M, Chang JC, Liu XS, Glimcher LH: XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature. 2014, 508: 103-107. 10.1038/nature13119.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rzymski T, Milani M, Pike L, Buffa F, Mellor HR, Winchester L, Pires I, Hammond E, Ragoussis I, Harris AL: Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene. 2010, 29: 4424-4435. 10.1038/onc.2010.191.
Article
CAS
PubMed
Google Scholar
Tang X, Lucas JE, Chen JL, LaMonte G, Wu J, Wang MC, Koumenis C, Chi JT: Functional interaction between responses to lactic acidosis and hypoxia regulates genomic transcriptional outputs. Cancer Res. 2012, 72: 491-502. 10.1158/0008-5472.CAN-11-2076.
Article
CAS
PubMed
Google Scholar
Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G: Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009, 106: 8368-8373. 10.1073/pnas.0903392106.
Article
CAS
PubMed
PubMed Central
Google Scholar
Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS, Karoly ED, Chan K, Samanta S, Prieto D, Hsu TY, Kurley SJ, Putluri V, Sonavane R, Edelman DC, Wulff J, Starks AM, Yang Y, Kittles RA, Yfantis HG, Lee DH, Ioffe OB, Schiff R, Stephens RM, Meltzer PS, et al: MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014, 124: 398-412. 10.1172/JCI71180.
Article
CAS
PubMed
Google Scholar
Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S, Tam A, Solow-Cordero DE, Bouley DM, Offner F, Niwa M, Koong AC: Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 2011, 117: 1311-1314. 10.1182/blood-2010-08-303099.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zaret KS, Carroll JS: Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 2011, 25: 2227-2241. 10.1101/gad.176826.111.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011, 121: 2750-2767. 10.1172/JCI45014.
Article
CAS
PubMed
PubMed Central
Google Scholar